Chester County News and Community Website
Galera Therapeutics, Inc. (Nasdaq: GRTX), headquartered in Malvern, PA, is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler …
Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy …
Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on …
Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) has announced interim data from the full patient population (n=42) in its Phase 1/2 clinical trial of avasopasem manganese (GC4419) in combination …
Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced the release of the abstract containing interim data from the first 19 patients in its pilot Phase 1/2 clinical trial designed …
Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that the first patient has been dosed in the Phase 1/2 GRECO-1 clinical trial of GC4711 in combination with stereotactic body …
Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy …
Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced the first patient has been dosed in a pilot Phase 2 clinical trial of lead product candidate avasopasem manganese (GC4419) to …
Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that Mel Sorensen, M.D., President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech …
Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that data from its double-blind, placebo-controlled pilot Phase 1b/2a clinical trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation …
Read More